 1. Goff DC. Maintenance treatment with long‐acting injectable antipsychotics: comparing old with new. JAMA 2014;311:1973‐4. [PubMed] [Google Scholar] 2. International College of Neuropsychopharmacology . CINP schizophrenia guidelines. http://cinp.org/cinp-schizophrenia-guidelines/. 3. Schimmelmann BG, Schmidt SJ, Carbon M et al. Treatment of adolescents with early‐onset schizophrenia spectrum disorders: in search of a rational, evidence‐informed approach. Curr Opin Psychiatry 2013;26:219‐30. [PubMed] [Google Scholar] 4. Newcomer JW, Weiden PJ, Buchanan RW. Switching antipsychotic medications to reduce adverse event burden in schizophrenia: establishing evidence‐based practice. J Clin Psychiatry 2013;74:1108‐20. [PubMed] [Google Scholar] 5. Stroup TS, McEvoy JP, Ring KD et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947‐56. [PMC free article] [PubMed] [Google Scholar] 6. Brar JS, Ganguli R, Pandina G et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2005;66:205‐12. [PubMed] [Google Scholar] 7. Seemuller F, Lewitzka U, Bauer M. The relationship of akathisia with treatment emergent suicidality among patients with first‐episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry 2012;45:292‐6. [PubMed] [Google Scholar] 8. Tarsy D. Neuroleptic‐induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol 1983;6(Suppl. 1):S9‐26. [PubMed] [Google Scholar] 9. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ 1999;319:623‐6. [PMC free article] [PubMed] [Google Scholar] 10. Keepers GA, Casey DE. Use of neuroleptic‐induced extrapyramidal symptoms to predict future vulnerability to side effects. Am J Psychiatry 1991;148:85‐9. [PubMed] [Google Scholar] 11. Aguilar EJ, Keshavan MS, Martinez‐Quiles MD et al. Predictors of acute dystonia in first‐episode psychotic patients. Am J Psychiatry 1994;151:1819‐21. [PubMed] [Google Scholar] 12. Swett C Jr. Drug‐induced dystonia. Am J Psychiatry 1975;132:532‐4. [PubMed] [Google Scholar] 13. Koek RJ, Pi EH. Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics 1989;30:359‐64. [PubMed] [Google Scholar] 14. Gardner DM, Abidi S, Ursuliak Z et al. Incidence of oculogyric crisis and long‐term outcomes with second‐generation antipsychotics in a first‐episode psychosis program. J Clin Psychopharmacol 2015;35:715‐8. [PubMed] [Google Scholar] 15. Arana GW, Goff DC, Baldessarini RJ et al. Efficacy of anticholinergic prophylaxis for neuroleptic‐induced acute dystonia. Am J Psychiatry 1988;145:993‐6. [PubMed] [Google Scholar] 16. Goff DC, Arana GW, Greenblatt DJ et al. The effect of benztropine on haloperidol‐induced dystonia, clinical efficacy and pharmacokinetics: a prospective, double‐blind trial. J Clin Psychopharmacol 1991;11:106‐12. [PubMed] [Google Scholar] 17. Stern TA, Anderson WH. Benztropine prophylaxis of dystonic reactions. Psychopharmacology 1979;61:261‐2. [PubMed] [Google Scholar] 18. Winslow RS, Stillner V, Coons DJ et al. Prevention of acute dystonic reactions in patients beginning high‐potency neuroleptics. Am J Psychiatry 1986;143:706‐10. [PubMed] [Google Scholar] 19. Swett C Jr, Cole JO, Shapiro S et al. Extrapyramidal side effects in chlorpromazine recipients: emergence according to benztropine prophylaxis. Arch Gen Psychiatry 1977;34:942‐3. [PubMed] [Google Scholar] 20. Desmarais JE, Beauclair L, Annable L et al. Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol 2014;4:257‐67. [PMC free article] [PubMed] [Google Scholar] 21. Caradoc‐Davies G, Menkes DB, Clarkson HO et al. A study of the need for anticholinergic medication in patients treated with long‐term antipsychotics. Aust N Z J Psychiatry 1986;20:225‐32. [PubMed] [Google Scholar] 22. Chan HY, Chang CJ, Chiang SC et al. A randomised controlled study of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced acute dystonia or parkinsonism. J Psychopharmacol 2010;24:91‐8. [PMC free article] [PubMed] [Google Scholar] 23. Altamura AC, Mauri MC, Mantero M et al. Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. Acta Psychiatr Scand 1987;76:702‐6. [PubMed] [Google Scholar] 24. Gagrat D, Hamilton J, Belmaker RH. Intravenous diazepam in the treatment of neuroleptic‐induced acute dystonia and akathisia. Am J Psychiatry 1978;135:1232‐3. [PubMed] [Google Scholar] 25. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009;85:322‐6. [PubMed] [Google Scholar] 26. Caligiuri MP, Lohr JB. Instrumental motor predictors of neuroleptic‐induced parkinsonism in newly medicated schizophrenia patients. J Neuropsychiatry Clin Neurosci 1997;9:562‐7. [PubMed] [Google Scholar] 27. Hriso E, Kuhn T, Masdeu JC et al. Extrapyramidal symptoms due to dopamine‐blocking agents in patients with AIDS encephalopathy. Am J Psychiatry 1991;148:1558‐61. [PubMed] [Google Scholar] 28. Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV‐associated psychosis and drug‐induced parkinsonism. Mov Disord 1999;14:128‐31. [PubMed] [Google Scholar] 29. Chang A, Fox SH. Psychosis in Parkinson's disease: epidemiology, pathophysiology, and management. Drugs 2016;76:1093‐18. [PubMed] [Google Scholar] 30. Samudra N, Patel N, Womack KB et al. Psychosis in Parkinson disease: a review of etiology, phenomenology, and management. Drugs Aging 2016;33:855‐63. [PMC free article] [PubMed] [Google Scholar] 31. Taylor J, Anderson WS, Brandt J et al. Neuropsychiatric complications of Parkinson disease treatments: importance of multidisciplinary care. Am J Geriatr Psychiatry 2016;24:1171‐80. [PMC free article] [PubMed] [Google Scholar] 32. Mamo DC, Sweet RA, Keshavan MS. Managing antipsychotic‐induced parkinsonism. Drug Saf 1999;20:269‐75. [PubMed] [Google Scholar] 33. Cortese L, Caligiuri MP, Williams R et al. Reduction in neuroleptic‐induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 2008;28:69‐73. [PubMed] [Google Scholar] 34. Magnus RV. A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug‐induced Parkinsonism. J Int Med Res 1980;8:343‐6. [PubMed] [Google Scholar] 35. Dayalu P, Chou KL. Antipsychotic‐induced extrapyramidal symptoms and their management. Expert Opin Pharmacother 2008;9:1451‐62. [PubMed] [Google Scholar] 36. Ananth J, Sangani H, Noonan JP. Amantadine in drug‐induced extrapyramidal signs: a comparative study. Int J Clin Pharmacol Biopharm 1975;11:323‐6. [PubMed] [Google Scholar] 37. Chouinard G, Annable L, Ross‐Chouinard A et al. Ethopropazine and benztropine in neuroleptic‐induced parkinsonism. J Clin Psychiatry 1979;40:147‐52. [PubMed] [Google Scholar] 38. Kelly JT, Zimmermann RL, Abuzzahab FS et al. A double‐blind study of amantadine hydrochloride versus benztropine mesylate in drug‐induced parkinsonism. Pharmacology 1974;12:65‐73. [PubMed] [Google Scholar] 39. Mindham RH, Gaind R, Anstee BH et al. Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine‐induced Parkinsonism. Psychol Med 1972;2:406‐13. [PubMed] [Google Scholar] 40. Silver H, Geraisy N, Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian‐ and tardive dyskinesia‐type involuntary movements: a double‐blind crossover, placebo‐controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry 1995;56:167‐70. [PubMed] [Google Scholar] 41. Van Putten T. Vulnerability to extrapyramidal side effects. Clin Neuropharmacol 1983;6(Suppl. 1):S27‐34. [PubMed] [Google Scholar] 42. Miller CH, Hummer M, Oberbauer H et al. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol 1997;7:51‐5. [PubMed] [Google Scholar] 43. Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug‐induced akathisia. Arch Gen Psychiatry 1994;51:963‐74. [PubMed] [Google Scholar] 44. Juncal‐Ruiz M, Ramirez‐Bonilla M, Gomez‐Arnau J et al. Incidence and risk factors of acute akathisia in 493 individuals with first episode non‐affective psychosis: a 6‐week randomised study of antipsychotic treatment. Psychopharmacology 2017;234:2563‐70. [PubMed] [Google Scholar] 45. Poyurovsky M. Acute antipsychotic‐induced akathisia revisited. Br J Psychiatry 2010;196:89‐91. [PubMed] [Google Scholar] 46. Poyurovsky M, Pashinian A, Weizman R et al. Low‐dose mirtazapine: a new option in the treatment of antipsychotic‐induced akathisia. A randomized, double‐blind, placebo‐ and propranolol‐controlled trial. Biol Psychiatry 2006;59:1071‐7. [PubMed] [Google Scholar] 47. Adler L, Angrist B, Peselow E et al. A controlled assessment of propranolol in the treatment of neuroleptic‐induced akathisia. Br J Psychiatry 1986;149:42‐5. [PubMed] [Google Scholar] 48. Kramer MS, Gorkin R, DiJohnson C. Treatment of neuroleptic‐induced akathisia with propranolol: a controlled replication study. Hillside J Clin Psychiatry 1989;11:107‐19. [PubMed] [Google Scholar] 49. Kramer MS, Gorkin RA, DiJohnson C et al. Propranolol in the treatment of neuroleptic‐induced akathisia (NIA) in schizophrenics: a double‐blind, placebo‐controlled study. Biol Psychiatry 1988;24:823‐7. [PubMed] [Google Scholar] 50. Lima AR, Bacalcthuk J, Barnes TR et al. Central action beta‐blockers versus placebo for neuroleptic‐induced acute akathisia. Cochrane Database Syst Rev 2004;4:CD001946. [PMC free article] [PubMed] [Google Scholar] 51. Rathbone J, Soares‐Weiser K. Anticholinergics for neuroleptic‐induced acute akathisia. Cochrane Database Syst Rev 2006;4:CD003727. [PMC free article] [PubMed] [Google Scholar] 52. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic‐induced akathisia. J Clin Psychopharmacol 1990;10:12‐21. [PubMed] [Google Scholar] 53. Hieber R, Dellenbaugh T, Nelson LA. Role of mirtazapine in the treatment of antipsychotic‐induced akathisia. Ann Pharmacother 2008;42:841‐6. [PubMed] [Google Scholar] 54. Praharaj SK, Kongasseri S, Behere RV et al. Mirtazapine for antipsychotic‐induced acute akathisia: a systematic review and meta‐analysis of randomized placebo‐controlled trials. Ther Adv Psychopharmacol 2015;5:307‐13. [PMC free article] [PubMed] [Google Scholar] 55. Miller CH, Fleischhacker WW, Ehrmann H et al. Treatment of neuroleptic induced akathisia with the 5‐HT2 antagonist ritanserin. Psychopharmacol Bull 1990;26:373‐6. [PubMed] [Google Scholar] 56. Miller CH, Hummer M, Pycha R et al. The effect of ritanserin on treatment‐resistant neuroleptic induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:247‐51. [PubMed] [Google Scholar] 57. Poyurovsky M, Fuchs C, Weizman A. Low‐dose mianserin in treatment of acute neuroleptic‐induced akathisia. J Clin Psychopharmacol 1998;18:253‐4. [PubMed] [Google Scholar] 58. Poyurovsky M, Shardorodsky M, Fuchs C et al. Treatment of neuroleptic‐induced akathisia with the 5‐HT2 antagonist mianserin. Double‐blind, placebo‐controlled study. Br J Psychiatry 1999;174:238‐42. [PubMed] [Google Scholar] 59. Avital A, Gross‐Isseroff R, Stryjer R et al. Zolmitriptan compared to propranolol in the treatment of acute neuroleptic‐induced akathisia: a comparative double‐blind study. Eur Neuropsychopharmacol 2009;19:476‐82. [PubMed] [Google Scholar] 60. Fischel T, Hermesh H, Aizenberg D et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic‐induced akathisia: a comparative double‐blind study. J Clin Psychopharmacol 2001;21:612‐5. [PubMed] [Google Scholar] 61. Hirose S, Ashby CR. Immediate effect of intravenous diazepam in neuroleptic‐induced acute akathisia: an open‐label study. J Clin Psychiatry 2002;63:524‐7. [PubMed] [Google Scholar] 62. Bartels M, Heide K, Mann K et al. Treatment of akathisia with lorazepam. An open clinical trial. Pharmacopsychiatry 1987;20:51‐3. [PubMed] [Google Scholar] 63. Kutcher S, Williamson P, MacKenzie S et al. Successful clonazepam treatment of neuroleptic‐induced akathisia in older adolescents and young adults: a double‐blind, placebo‐controlled study. J Clin Psychopharmacol 1989;9:403‐6. [PubMed] [Google Scholar] 64. Pujalte D, Bottai T, Hue B et al. A double‐blind comparison of clonazepam and placebo in the treatment of neuroleptic‐induced akathisia. Clin Neuropharmacol 1994;17:236‐42. [PubMed] [Google Scholar] 65. Lima AR, Soares‐Weiser K, Bacaltchuk J et al. Benzodiazepines for neuroleptic‐induced acute akathisia. Cochrane Database Syst Rev 2002;1:CD001950. [PMC free article] [PubMed] [Google Scholar] 66. Tiihonen J, Mittendorfer‐Rutz E, Torniainen M et al. Mortality and cumulative exposure to antipsychotics, antidepressants, and benzodiazepines in patients with schizophrenia: an observational follow‐up study. Am J Psychiatry 2016;173:600‐6. [PubMed] [Google Scholar] 67. Lerner V, Bergman J, Statsenko N et al. Vitamin B6 treatment in acute neuroleptic‐induced akathisia: a randomized, double‐blind, placebo‐controlled study. J Clin Psychiatry 2004;65:1550‐4. [PubMed] [Google Scholar] 68. Bernstein AL. Vitamin B6 in clinical neurology. Ann N Y Acad Sci 1990;585:250‐60. [PubMed] [Google Scholar] 69. Erdur B, Tura P, Aydin B et al. A trial of midazolam vs diphenhydramine in prophylaxis of metoclopramide‐induced akathisia. Am J Emerg Med 2012;30:84‐91. [PubMed] [Google Scholar] 70. Friedman BW, Bender B, Davitt M et al. A randomized trial of diphenhydramine as prophylaxis against metoclopramide‐induced akathisia in nauseated emergency department patients. Ann Emerg Med 2009;53:379‐85. [PubMed] [Google Scholar] 71. Vinson DR. Diphenhydramine in the treatment of akathisia induced by prochlorperazine. J Emerg Med 2004;26:265‐70. [PubMed] [Google Scholar] 72. Cornett EM, Novitch M, Kaye AD et al. Medication‐induced tardive dyskinesia: a review and update. Ochsner J 2017;17:162‐74. [PMC free article] [PubMed] [Google Scholar] 73. Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J 2011;87:132‐41. [PubMed] [Google Scholar] 74. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr Bull 1992;18:701‐15. [PubMed] [Google Scholar] 75. Tenback DE, van Harten PN, Slooff CJ et al. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiatry 2006;163:1438‐40. [PubMed] [Google Scholar] 76. Tenback DE, van Harten PN, van Os J. Non‐therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta‐analysis. Mov Disord 2009;24:2309‐15. [PubMed] [Google Scholar] 77. Miller DD, McEvoy JP, Davis SM et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 2005;80:33‐43. [PubMed] [Google Scholar] 78. Zhang XY, Chen DC, Qi LY et al. Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology 2009;205:647‐54. [PubMed] [Google Scholar] 79. Bakker PR, van Harten PN, van Os J. Antipsychotic‐induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta‐analysis of pharmacogenetic interactions. Mol Psychiatry 2008;13:544‐56. [PubMed] [Google Scholar] 80. Zai CC, Tiwari AK, Muller DJ et al. The catechol‐O‐methyl‐transferase gene in tardive dyskinesia. World J Biol Psychiatry 2010;11:803‐12. [PubMed] [Google Scholar] 81. Miura I, Zhang JP, Nitta M et al. BDNF Val66Met polymorphism and antipsychotic‐induced tardive dyskinesia occurrence and severity: a meta‐analysis. Schizophr Res 2014;152:365‐72. [PMC free article] [PubMed] [Google Scholar] 82. Inada T, Koga M, Ishiguro H et al. Pathway‐based association analysis of genome‐wide screening data suggest that genes associated with the gamma‐aminobutyric acid receptor signaling pathway are involved in neuroleptic‐induced, treatment‐resistant tardive dyskinesia. Pharmacogenet Gen 2008;18:317‐23. [PubMed] [Google Scholar] 83. Lanning RK, Zai CC, Muller DJ. Pharmacogenetics of tardive dyskinesia: an updated review of the literature. Pharmacogenomics 2016;17:1339‐51. [PubMed] [Google Scholar] 84. Son WY, Lee HJ, Yoon HK et al. GABA transporter SLC6A11 gene polymorphism associated with tardive dyskinesia. Nordic J Psychiatry 2014;68:123‐8. [PubMed] [Google Scholar] 85. Carbon M, Hsieh CH, Kane JM et al. Tardive dyskinesia prevalence in the period of second‐generation antipsychotic use: a meta‐analysis. J Clin Psychiatry 2017;78:e264‐78. [PubMed] [Google Scholar] 86. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151‐6. [PubMed] [Google Scholar] 87. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second‐generation antipsychotics: a systematic review of 1‐year studies. Am J Psychiatry 2004;161:414‐25. [PubMed] [Google Scholar] 88. O'Brien A. Comparing the risk of tardive dyskinesia in older adults with first‐generation and second‐generation antipsychotics: a systematic review and meta‐analysis. Int J Geriatr Psychiatry 2016;31:683‐93. [PubMed] [Google Scholar] 89. Bai YM, Yu SC, Chen JY et al. Risperidone for pre‐existing severe tardive dyskinesia: a 48‐week prospective follow‐up study. Int Clin Psychopharmacol 2005;20:79‐85. [PubMed] [Google Scholar] 90. Chan HY, Chiang SC, Chang CJ et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic‐induced tardive dyskinesia. J Clin Psychiatry 2010;71:1226‐33. [PubMed] [Google Scholar] 91. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995;15:36S‐44S. [PubMed] [Google Scholar] 92. Bergman H, Walker DM, Nikolakopoulou A et al. Systematic review of interventions for treating or preventing antipsychotic‐induced tardive dyskinesia. Health Technol Assess 2017;21:1‐218. [PMC free article] [PubMed] [Google Scholar] 93. Hauser RA, Factor SA, Marder SR et al. KINECT 3: a phase 3 randomized, double‐blind, placebo‐controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry 2017;174:476‐84. [PubMed] [Google Scholar] 94. Leung JG, Breden EL. Tetrabenazine for the treatment of tardive dyskinesia. Ann Pharmacother 2011;45:525‐31. [PubMed] [Google Scholar] 95. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279‐81. [PubMed] [Google Scholar] 96. Citrome L. Valbenazine for tardive dyskinesia: a systematic review of the efficacy and safety profile for this newly approved novel medication – what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract (in press). [PubMed] [Google Scholar] 97. Fernandez HH, Factor SA, Hauser RA et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM‐TD study. Neurology 2017;88:2003‐10. [PMC free article] [PubMed] [Google Scholar] 98. Alabed S, Latifeh Y, Mohammad HA et al. Gamma‐aminobutyric acid agonists for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2011;4:CD000203. [PubMed] [Google Scholar] 99. Thaker GK, Nguyen JA, Strauss ME et al. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147:445‐51. [PubMed] [Google Scholar] 100. Zhang WF, Tan YL, Zhang XY et al. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double‐blind, placebo‐controlled trial. J Clin Psychiatry 2011;72:615‐21. [PubMed] [Google Scholar] 101. Zhang XY, Zhang WF, Zhou DF et al. Brain‐derived neurotrophic factor levels and its Val66Met gene polymorphism predict tardive dyskinesia treatment response to Ginkgo biloba. Biol Psychiatry 2012;72:700‐6. [PubMed] [Google Scholar] 102. Adelufosi AO, Abayomi O, Ojo TM. Pyridoxal 5 phosphate for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2015;4:CD010501. [PubMed] [Google Scholar] 103. Soares‐Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2011;2:CD000209. [PubMed] [Google Scholar] 104. Bhidayasiri R, Fahn S, Weiner WJ et al. Evidence‐based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2013;81:463‐9. [PubMed] [Google Scholar] 105. El‐Sayeh HG, Lyra da Silva JP, Rathbone J et al. Non‐neuroleptic catecholaminergic drugs for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2006;1:CD000458. [PubMed] [Google Scholar] 106. Essali A, Deirawan H, Soares‐Weiser K et al. Calcium channel blockers for neuroleptic‐induced tardive dyskinesia. Cochrane Database Syst Rev 2011;11:CD000206. [PubMed] [Google Scholar] 107. Pouclet‐Courtemanche H, Rouaud T, Thobois S et al. Long‐term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology 2016;86:651‐9. [PubMed] [Google Scholar] 108. Saleh C, Gonzalez V, Coubes P. Role of deep brain stimulation in the treatment of secondary dystonia‐dyskinesia syndromes. Handb Clin Neurol 2013;116:189‐208. [PubMed] [Google Scholar] 109. Sobstyl M, Zabek M. Deep brain stimulation for intractable tardive dystonia: literature overview. Neurol Neurochir Pol 2016;50:114‐22. [PubMed] [Google Scholar] 110. Thobois S, Poisson A, Damier P. Surgery for tardive dyskinesia. Int Rev Neurobiol 2011;98:289‐96. [PubMed] [Google Scholar] 111. Maher S, Cunningham A, O'Callaghan N et al. Clozapine‐induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. Ther Adv Psychopharmacol 2016;6:178‐84. [PMC free article] [PubMed] [Google Scholar] 112. Corrigan FM, MacDonald S, Reynolds GP. Clozapine‐induced hypersalivation and the alpha 2 adrenoceptor. Br J Psychiatry 1995;167:412. [PubMed] [Google Scholar] 113. Ukai Y, Taniguchi N, Ishima T et al. Muscarinic supersensitivity and subsensitivity induced by chronic treatment with atropine and diisopropylfluorophosphate in rat submaxillary glands. Arch Int Pharmacodyn Ther 1989;297:148‐57. [PubMed] [Google Scholar] 114. Saenger RC, Finch TH, Francois D. Aspiration pneumonia due to clozapine‐induced sialorrhea. Clin Schizophr Relat Psychoses 2016;9:170‐2. [PubMed] [Google Scholar] 115. Trigoboff E, Grace J, Szymanski H et al. Sialorrhea and aspiration pneumonia: a case study. Innov Clin Neurosci 2013;10:20‐7. [PMC free article] [PubMed] [Google Scholar] 116. Acosta‐Armas AJ. Two cases of parotid gland swelling in patients taking clozapine. Hosp Med 2001;62:704‐5. [PubMed] [Google Scholar] 117. Patkar AA, Alexander RC. Parotid gland swelling with clozapine. J Clin Psychiatry 1996;57:488. [PubMed] [Google Scholar] 118. Bird AM, Smith TL, Walton AE. Current treatment strategies for clozapine‐induced sialorrhea. Ann Pharmacother 2011;45:667‐75. [PubMed] [Google Scholar] 119. Essali A, Rihawi A, Altujjar M et al. Anticholinergic medication for non‐clozapine neuroleptic‐induced hypersalivation in people with schizophrenia. Cochrane Database Syst Rev 2013;12:CD009546. [PubMed] [Google Scholar] 120. Antonello C, Tessier P. Clozapine and sialorrhea: a new intervention for this bothersome and potentially dangerous side effect. J Psychiatry Neurosci 1999;24:250. [PMC free article] [PubMed] [Google Scholar] 121. Sharma A, Ramaswamy S, Dahl E et al. Intraoral application of atropine sulfate ophthalmic solution for clozapine‐induced sialorrhea. Ann Pharmacother 2004;38:1538. [PubMed] [Google Scholar] 122. Tessier P, Antonello C. Clozapine and sialorrhea: update. J Psychiatry Neurosci 2001;26:253. [PMC free article] [PubMed] [Google Scholar] 123. Calderon J, Rubin E, Sobota WL. Potential use of ipratropium bromide for the treatment of clozapine‐induced hypersalivation: a preliminary report. Int Clin Psychopharmacol 2000;15:49‐52. [PubMed] [Google Scholar] 124. Freudenreich O, Beebe M, Goff DC. Clozapine‐induced sialorrhea treated with sublingual ipratropium spray: a case series. J Clin Psychopharmacol 2004;24:98‐100. [PubMed] [Google Scholar] 125. Sockalingam S, Shammi C, Remington G. Treatment of clozapine‐induced hypersalivation with ipratropium bromide: a randomized, double‐blind, placebo‐controlled crossover study. J Clin Psychiatry 2009;70:1114‐9. [PubMed] [Google Scholar] 126. Reinstein M, Sirotovskaya L, Chasanov M et al. Comparative efficacy and tolerability of benztropine and terazosin in the treatment of hypersalivation secondary to clozapine. Clin Drug Invest 1999;17:97‐102. [Google Scholar] 127. Spivak B, Adlersberg S, Rosen L et al. Trihexyphenidyl treatment of clozapine‐induced hypersalivation. Int Clin Psychopharmacol 1997;12:213‐5. [PubMed] [Google Scholar] 128. Liang CS, Ho PS, Shen LJ et al. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine‐induced sialorrhea in schizophrenic patients: a randomized, double‐blind, crossover study. Schizophr Res 2010;119:138‐44. [PubMed] [Google Scholar] 129. Bai YM, Lin CC, Chen JY et al. Therapeutic effect of pirenzepine for clozapine‐induced hypersalivation: a randomized, double‐blind, placebo‐controlled, cross‐over study. J Clin Psychopharmacol 2001;21:608‐11. [PubMed] [Google Scholar] 130. Schneider B, Weigmann H, Hiemke C et al. Reduction of clozapine‐induced hypersalivation by pirenzepine is safe. Pharmacopsychiatry 2004;37:43‐5. [PubMed] [Google Scholar] 131. Copp PJ, Lament R, Tennent TG. Amitriptyline in clozapine‐induced sialorrhoea. Br J Psychiatry 1991;159:166. [PubMed] [Google Scholar] 132. Grabowski J. Clonidine treatment of clozapine‐induced hypersalivation. J Clin Psychopharmacol 1992;12:69‐70. [PubMed] [Google Scholar] 133. Praharaj SK, Verma P, Roy D et al. Is clonidine useful for treatment of clozapine‐induced sialorrhea? J Psychopharmacol 2005;19:426‐8. [PubMed] [Google Scholar] 134. Webber MA, Szwast SJ, Steadman TM et al. Guanfacine treatment of clozapine‐induced sialorrhea. J Clin Psychopharmacol 2004;24:675‐6. [PubMed] [Google Scholar] 135. Kreinin A, Epshtein S, Sheinkman A et al. Sulpiride addition for the treatment of clozapine‐induced hypersalivation: preliminary study. Isr J Psychiatry Relat Sci 2005;42:61‐3. [PubMed] [Google Scholar] 136. Kreinin A, Miodownik C, Sokolik S et al. Amisulpride versus moclobemide in treatment of clozapine‐induced hypersalivation. World J Biol Psychiatry 2011;12:620‐6. [PubMed] [Google Scholar] 137. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine‐induced hypersalivation in schizophrenia patients: a randomized, double‐blind, placebo‐controlled cross‐over study. Int Clin Psychopharmacol 2006;21:99‐103. [PubMed] [Google Scholar] 138. Kreinin A, Miodownik C, Libov I et al. Moclobemide treatment of clozapine‐induced hypersalivation: pilot open study. Clin Neuropharmacol 2009;32:151‐3. [PubMed] [Google Scholar] 139. Kahl KG, Hagenah J, Zapf S et al. Botulinum toxin as an effective treatment of clozapine‐induced hypersalivation. Psychopharmacology 2004;173:229‐30. [PubMed] [Google Scholar] 140. Steinlechner S, Klein C, Moser A et al. Botulinum toxin B as an effective and safe treatment for neuroleptic‐induced sialorrhea. Psychopharmacology 2010;207:593‐7. [PubMed] [Google Scholar] 141. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple‐treatments meta‐analysis. Lancet 2013;382:951‐62. [PubMed] [Google Scholar] 142. Masopust J, Maly R, Valis M. Risk of venous thromboembolism during treatment with antipsychotic agents. Psychiatry Clin Neurosci 2012;66:541‐52. [PubMed] [Google Scholar] 143. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6(Suppl. 2):3‐7. [PMC free article] [PubMed] [Google Scholar] 144. Andrade C, Kisely S, Monteiro I et al. Antipsychotic augmentation with modafinil or armodafinil for negative symptoms of schizophrenia: systematic review and meta‐analysis of randomized controlled trials. J Psychiatr Res 2015;60:14‐21. [PubMed] [Google Scholar] 145. Burke M, Sebastian CS. Treatment of clozapine sedation. Am J Psychiatry 1993;150:1900‐1. [PubMed] [Google Scholar] 146. Carpenter MD, Winsberg BG, Camus LA. Methylphenidate augmentation therapy in schizophrenia. J Clin Psychopharmacol 1992;12:273‐5. [PubMed] [Google Scholar] 147. Szeszko PR, Bilder RM, Dunlop JA et al. Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first‐episode schizophrenia at acute and stabilized phases. Biol Psychiatry 1999;45:680‐6. [PubMed] [Google Scholar] 148. Makela EH, Miller K, Cutlip WD 2nd. Three case reports of modafinil use in treating sedation induced by antipsychotic medications. J Clin Psychiatry 2003;64:485‐6. [PubMed] [Google Scholar] 149. Saavedra‐Velez C, Yusim A, Anbarasan D et al. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry 2009;70:104‐12. [PubMed] [Google Scholar] 150. Freudenreich O, Henderson DC, Macklin EA et al. Modafinil for clozapine‐treated schizophrenia patients: a double‐blind, placebo‐controlled pilot trial. J Clin Psychiatry 2009;70:1674‐80. [PMC free article] [PubMed] [Google Scholar] 151. Miller SC. Methylphenidate for clozapine sedation. Am J Psychiatry 1996;153:1231‐2. [PubMed] [Google Scholar] 152. Saraf G, Viswanath B, Narayanaswamy JC et al. Modafinil for the treatment of antipsychotic‐induced excessive daytime sedation: does it exacerbate tics? J Neuropsychiatry Clin Neurosci 2013;25:E35‐6. [PubMed] [Google Scholar] 153. Chen CY, Lane HY, Lin CH. Effects of antipsychotics on bone mineral density in patients with schizophrenia: gender differences. Clin Psychopharmacol Neurosci 2016;14:238‐49. [PMC free article] [PubMed] [Google Scholar] 154. Kollin E, Gergely I, Szucs J et al. Decreased bone density in hyperprolactinemic women. N Engl J Med 1981;304:1362‐3. [PubMed] [Google Scholar] 155. Gonzalez‐Blanco L, Greenhalgh AM, Garcia‐Rizo C et al. Prolactin concentrations in antipsychotic‐naive patients with schizophrenia and related disorders: a meta‐analysis. Schizophr Res 2016;174:156‐60. [PubMed] [Google Scholar] 156. La Torre A, Conca A, Duffy D et al. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 2013;46:201‐8. [PubMed] [Google Scholar] 157. de Boer MK, Castelein S, Bous J et al. The Antipsychotics and Sexual Functioning Questionnaire (ASFQ): preliminary evidence for reliability and validity. Schizophr Res 2013;150:410‐5. [PubMed] [Google Scholar] 158. Compton MT, Miller AH. Antipsychotic‐induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36:143‐64. [PubMed] [Google Scholar] 159. Serretti A, Chiesa A. A meta‐analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011;26:130‐40. [PubMed] [Google Scholar] 160. Berner MM, Hagen M, Kriston L. Management of sexual dysfunction due to antipsychotic drug therapy. Cochrane Database Syst Rev 2007;1:CD003546. [PubMed] [Google Scholar] 161. Renn JH, Yang NP, Chueh CM et al. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord 2009;10:1. [PMC free article] [PubMed] [Google Scholar] 162. Stubbs B, De Hert M, Sepehry AA et al. A meta‐analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia. Acta Psychiatr Scand 2014;130:470‐86. [PubMed] [Google Scholar] 163. Howard L, Kirkwood G, Leese M. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 2007;190:129‐34. [PubMed] [Google Scholar] 164. Lin CH, Lin CY, Huang TL et al. Sex‐specific factors for bone density in patients with schizophrenia. Int Clin Psychopharmacol 2015;30:96‐102. [PubMed] [Google Scholar] 165. Catala‐Lopez F, Suarez‐Pinilla M, Suarez‐Pinilla P et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta‐analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom 2014;83:89‐105. [PubMed] [Google Scholar] 166. De Hert M, Peuskens J, Sabbe T et al. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review. Acta Psychiatr Scand 2016;133:5‐22. [PubMed] [Google Scholar] 167. Holt RI, Peveler RC. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin Endocrinol 2011;74:141‐7. [PubMed] [Google Scholar] 168. Lehman AF, Lieberman JA, Dixon LB et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1‐56. [PubMed] [Google Scholar] 169. Peveler RC, Branford D, Citrome L et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22:98‐103. [PubMed] [Google Scholar] 170. Hernandez CJ, Beaupre GS, Carter DR. A theoretical analysis of the relative influences of peak BMD, age‐related bone loss and menopause on the development of osteoporosis. Osteoporos Int 2003;14:843‐7. [PubMed] [Google Scholar] 171. Tworoger SS, Eliassen AH, Sluss P et al. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J Clin Oncol 2007;25:1482‐8. [PubMed] [Google Scholar] 172. Kane JM, Correll CU, Goff DC et al. A multicenter, randomized, double‐blind, placebo‐controlled, 16‐week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009;70:1348‐57. [PubMed] [Google Scholar] 173. Chang SC, Chen CH, Lu ML. Cabergoline‐induced psychotic exacerbation in schizophrenic patients. Gen Hosp Psychiatry 2008;30:378‐80. [PubMed] [Google Scholar] 174. Costa AM, Lima MS, Mari Jde J. A systematic review on clinical management of antipsychotic‐induced sexual dysfunction in schizophrenia. Sao Paulo Med J 2006;124:291‐7. [PubMed] [Google Scholar] 175. Gugger JJ. Antipsychotic pharmacotherapy and orthostatic hypotension: identification and management. CNS Drugs 2011;25:659‐71. [PubMed] [Google Scholar] 176. Drici MD, Priori S. Cardiovascular risks of atypical antipsychotic drug treatment. Pharmacoepidemiol Drug Safety 2007;16:882‐90. [PubMed] [Google Scholar] 177. Stroup TS, Lieberman JA, McEvoy JP et al. Results of phase 3 of the CATIE schizophrenia trial. Schizophr Res 2009;107:1‐12. [PMC free article] [PubMed] [Google Scholar] 178. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second‐generation antipsychotic. Int J Clin Pract 2009;63:1237‐48. [PubMed] [Google Scholar] 179. Leung JY, Barr AM, Procyshyn RM et al. Cardiovascular side‐effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 2012;135:113‐22. [PubMed] [Google Scholar] 180. Freeman R. Current pharmacologic treatment for orthostatic hypotension. Clin Autonom Res 2008;18(Suppl. 1):14‐8. [PubMed] [Google Scholar] 181. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med 2010;77:298‐306. [PMC free article] [PubMed] [Google Scholar] 182. Testani M Jr. Clozapine‐induced orthostatic hypotension treated with fludrocortisone. J Clin Psychiatry 1994;55:497‐8. [PubMed] [Google Scholar] 183. Kurihara J, Takata Y, Suzuki S et al. Effect of midodrine on chlorpromazine‐induced orthostatic hypotension in rabbits: comparison with amezinium, etilefrine and droxidopa. Biol Pharmaceut Bull 2000;23:1445‐9. [PubMed] [Google Scholar] 184. Castrioto A, Tambasco N, Rossi A et al. Acute dystonia induced by the combination of midodrine and perphenazine. J Neurol 2008;255:767‐8. [PubMed] [Google Scholar] 185. Takahashi H. Acute dystonia induced by adding midodrine, a selective alpha 1 agonist, to risperidone in a patient with catatonic schizophrenia. J Neuropsychiatry Clin Neurosci 2000;12:285‐6. [PubMed] [Google Scholar] 186. Hou PY, Hung GC, Jhong JR et al. Risk factors for sudden cardiac death among patients with schizophrenia. Schizophr Res 2015;168:395‐401. [PubMed] [Google Scholar] 187. Ray WA, Chung CP, Murray KT et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225‐35. [PMC free article] [PubMed] [Google Scholar] 188. Straus SM, Bleumink GS, Dieleman JP et al. Antipsychotics and the risk of sudden cardiac death. Arch Int Med 2004;164:1293‐7. [PubMed] [Google Scholar] 189. Wu CS, Tsai YT, Tsai HJ. Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation‐wide case‐crossover study. J Am Heart Assoc 2015;4:e001568. [PMC free article] [PubMed] [Google Scholar] 190. Mehtonen OP, Aranko K, Malkonen L et al. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 1991;84:58‐64. [PubMed] [Google Scholar] 191. Reilly JG, Ayis SA, Ferrier IN et al. Thioridazine and sudden unexplained death in psychiatric in‐patients. Br J Psychiatry 2002;180:515‐22. [PubMed] [Google Scholar] 192. Ray WA, Meredith S, Thapa PB et al. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161‐7. [PubMed] [Google Scholar] 193. Haddad PM, Anderson IM. Antipsychotic‐related QTc prolongation, torsade de pointes and sudden death. Drugs 2002;62:1649‐71. [PubMed] [Google Scholar] 194. Heist EK, Ruskin JN. Drug‐induced proarrhythmia and use of QTc‐prolonging agents: clues for clinicians. Heart Rhythm 2005;2:S1‐8. [PubMed] [Google Scholar] 195. Schneeweiss S, Avorn J. Antipsychotic agents and sudden cardiac death – how should we manage the risk? N Engl J Med 2009;360:294‐6. [PubMed] [Google Scholar] 196. Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract 2014;20:196‐206. [PubMed] [Google Scholar] 197. Lieberman JA, Merrill D, Parameswaran S. APA guidance on the use of antipsychotic drugs and cardiac sudden death. https://www.omh.ny.gov. 198. Kavanaugh G, Brown G, Khan I et al. Guidance on the use of antipsychotics, Version 3.2. London: National Health Service, 2015. [Google Scholar] 199. Pileggi DJ, Cook AM. Neuroleptic malignant syndrome. Ann Pharmacother 2016;50:973‐81. [PubMed] [Google Scholar] 200. Trollor JN, Chen X, Chitty K et al. Comparison of neuroleptic malignant syndrome induced by first‐ and second‐generation antipsychotics. Br J Psychiatry 2012;201:52‐6. [PubMed] [Google Scholar] 201. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009;23:477‐92. [PubMed] [Google Scholar] 202. Nielsen RE, Wallenstein Jensen SO, Nielsen J. Neuroleptic malignant syndrome – an 11‐year longitudinal case‐control study. Can J Psychiatry 2012;57:512‐8. [PubMed] [Google Scholar] 203. Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870‐6. [PubMed] [Google Scholar] 204. Su YP, Chang CK, Hayes RD et al. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatr Scand 2014;130:52‐60. [PubMed] [Google Scholar] 205. Tse L, Barr AM, Scarapicchia V et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol 2015;13:395‐406. [PMC free article] [PubMed] [Google Scholar] 206. Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998;44:499‐507. [PubMed] [Google Scholar] 207. Patil BS, Subramanyam AA, Singh SL et al. Low serum iron as a possible risk factor for neuroleptic malignant syndrome. Int J Appl Basic Med Res 2014;4:117‐8. [PMC free article] [PubMed] [Google Scholar] 208. Rosebush PI, Mazurek MF. Serum iron and neuroleptic malignant syndrome. Lancet 1991;338:149‐51. [PubMed] [Google Scholar] 209. Patel AL, Shaikh WA, Khobragade AK et al. Electroconvulsive therapy in drug resistant neuroleptic malignant syndrome. J Assoc Physicians India 2008;56:49‐50. [PubMed] [Google Scholar] 210. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993;77:185‐202. [PubMed] [Google Scholar] 211. Wells AJ, Sommi RW, Crismon ML. Neuroleptic rechallenge after neuroleptic malignant syndrome: case report and literature review. Drug Intell Clin Pharm 1988;22:475‐80. [PubMed] [Google Scholar] 212. Rosebush PI, Stewart TD, Gelenberg AJ. Twenty neuroleptic rechallenges after neuroleptic malignant syndrome in 15 patients. J Clin Psychiatry 1989;50:295‐8. [PubMed] [Google Scholar] 213. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999;33:650‐9. [PubMed] [Google Scholar] 214. Idänpään‐Heikkilä J, Alhava E, Olkinuora M et al. Clozapine and agranulocytosis. Lancet 1975;306:611. [PubMed] [Google Scholar] 215. Alvir JM, Lieberman JA, Safferman AZ et al. Clozapine‐induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329:162‐7. [PubMed] [Google Scholar] 216. Canoso RT, Lewis ME, Yunis EJ. Association of HLA‐Bw44 with chlorpromazine‐induced autoantibodies. Clin Immunol Immunopathol 1982;25:278‐82. [PubMed] [Google Scholar] 217. Fiore JM, Francis MN. Agranulocytosis due to mepazine (phenothiazine): report of three cases. N Engl J Med 1959;260:375‐8. [PubMed] [Google Scholar] 218. Goldman D. Agranulocytosis associated with administration of chlorpromazine: report of three cases with description of treatment and recovery. AMA Arch Int Med 1955;96:496. [PubMed] [Google Scholar] 219. Stergiou V, Bozikas VP, Garyfallos G et al. Olanzapine‐induced leucopenia and neutropenia. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:992‐4. [PubMed] [Google Scholar] 220. Sluys M, Güzelcan Y, Casteelen G et al. Risperidone‐induced leucopenia and neutropenia: a case report. Eur Psychiatry 2004;19:117. [PubMed] [Google Scholar] 221. Munro J, O'Sullivan D, Andrews C et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999;175:576‐80. [PubMed] [Google Scholar] 222. Sporn A, Gogtay N, Ortiz‐Aguayo R et al. Clozapine‐induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003;13:401‐4. [PubMed] [Google Scholar] 223. Papetti F, Darcourt G, Giordana J‐Y et al. Treatment of clozapine‐induced granulocytopenia with lithium (two observations). Encéphale 2004;30:578‐82. [PubMed] [Google Scholar] 224. Yadav D, Burton S, Sehgal C. Clozapine‐induced neutropenia reversed by lithium. Prog Neurol Psychiatry 2016;20:13‐5. [Google Scholar] 225. Nielsen H. Recombinant human granulocyte colony‐stimulating factor (rhG‐CSF; filgrastim) treatment of clozapine‐induced agranulocytosis. J Int Med 1993;234:529‐31. [PubMed] [Google Scholar] 226. Lamberti JS, Bellnier TJ, Schwarzkopf SB et al. Filgrastim treatment of three patients with clozapine‐induced agranulocytosis. J Clin Psychiatry 1995;56:256‐9. [PubMed] [Google Scholar] 227. Simon L, Cazard F. Clozapine rechallenge after neutropenia in resistant schizophrenia: a review. Encéphale 2016;42:346‐53. [PubMed] [Google Scholar] 228. Gaboriau L, Victorri‐Vigneau C, Gérardin M et al. Aripiprazole: a new risk factor for pathological gambling? A report of 8 case reports. Addict Behav 2014;39:562‐5. [PubMed] [Google Scholar] 229. Smith N, Kitchenham N, Bowden‐Jones H. Pathological gambling and the treatment of psychosis with aripiprazole: case reports. Br J Psychiatry 2011;199:158‐9. [PubMed] [Google Scholar] 230. Nirenberg MJ, Waters C. Compulsive eating and weight gain related to dopamine agonist use. Mov Disord 2006;21:524‐9. [PubMed] [Google Scholar] 231. Claassen DO, van den Wildenberg WP, Ridderinkhof KR et al. The risky business of dopamine agonists in Parkinson disease and impulse control disorders. Behav Neurosci 2011;125:492‐500. [PMC free article] [PubMed] [Google Scholar] 232. Etminan M, Sodhi M, Samii A et al. Risk of gambling disorder and impulse control disorder with aripiprazole, pramipexole, and ropinirole: a pharmacoepidemiologic study. J Clin Psychopharmacol 2017;37:102‐4. [PubMed] [Google Scholar] 233. Cheon E, Koo BH, Seo SS et al. Two cases of hypersexuality probably associated with aripiprazole. Psychiatry Invest 2013;10:200‐2. [PMC free article] [PubMed] [Google Scholar] 234. Cohen J, Magalon D, Boyer L et al. Aripiprazole‐induced pathological gambling: a report of 3 cases. Curr Drug Saf 2011;6:51‐3. [PubMed] [Google Scholar] 235. Haas SJ, Hill R, Krum H et al. Clozapine‐associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993‐2003. Drug Saf 2007;30:47‐57. [PubMed] [Google Scholar] 236. Ronaldson K, Fitzgerald P, Taylor A et al. Clinical course and analysis of ten fatal cases of clozapine‐induced myocarditis and comparison with 66 surviving cases. Schizophr Res 2011;128:161‐5. [PubMed] [Google Scholar] 237. Chopra N, de Leon J. Clozapine‐induced myocarditis may be associated with rapid titration: a case report verified with autopsy. Int J Psychiatry Med 2016;51:104‐15. [PubMed] [Google Scholar] 238. Youssef DL, Narayanan P, Gill N. Incidence and risk factors for clozapine‐induced myocarditis and cardiomyopathy at a regional mental health service in Australia. Australas Psychiatry 2016;24:176‐80. [PubMed] [Google Scholar] 239. Freudenreich O. Clozapine‐induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand 2015;132:240‐1. [PubMed] [Google Scholar] 240. Ellis PM, Cameron CR. Clozapine‐induced myocarditis and baseline echocardiograms. Aust N Z J Psychiatry 2012;46:1005‐6. [PubMed] [Google Scholar] 241. Ittasakul P, Archer A, Kezman J et al. Rapid re‐challenge with clozapine following pronounced myocarditis in a treatment‐resistance schizophrenia patient. Clin Schizophr Relat Psychoses 2013;10:120‐2. [PubMed] [Google Scholar] 242. Ganguli R. Behavioral therapy for weight loss in patients with schizophrenia. J Clin Psychiatry 2007;68(Suppl. 4):19‐25. [PubMed] [Google Scholar] 243. Daumit GL, Dickerson FB, Wang NY et al. A behavioral weight‐loss intervention in persons with serious mental illness. N Engl J Med 2013;368:1594‐602. [PMC free article] [PubMed] [Google Scholar] 244. Bartels SJ, Pratt SI, Aschbrenner KA et al. Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. Am J Psychiatry 2015;172:344‐52. [PMC free article] [PubMed] [Google Scholar] 245. Green CA, Yarborough BJ, Leo MC et al. The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial. Am J Psychiatry 2015;172:71‐81. [PMC free article] [PubMed] [Google Scholar] 246. Wu RR, Zhao JP, Guo XF et al. Metformin addition attenuates olanzapine‐induced weight gain in drug‐naive first‐episode schizophrenia patients: a double‐blind, placebo‐controlled study. Am J Psychiatry 2008;165:352‐8. [PubMed] [Google Scholar] 247. Wu RR, Zhao JP, Jin H et al. Lifestyle intervention and metformin for treatment of antipsychotic induced weight gain: a randomized controlled trial. JAMA 2008;299:185‐93. [PubMed] [Google Scholar] 248. Jarskog LF, Hamer RM, Catellier DJ et al. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry 2013;170:1032‐40. [PMC free article] [PubMed] [Google Scholar] 249. Baptista T, Rangel N, Fernández V et al. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double‐blind, placebo‐controlled trial. Schizophr Res 2007;93:99‐108. [PubMed] [Google Scholar] 250. Tek C, Ratliff J, Reutenauer E et al. A randomized, double‐blind, placebo‐controlled pilot study of naltrexone to counteract antipsychotic‐associated weight gain: proof of concept. J Clin Psychopharmacol 2014;34:608‐12. [PMC free article] [PubMed] [Google Scholar] 251. Lieberman JA 3rd. Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry 2004;6(Suppl. 2):20‐3. [PMC free article] [PubMed] [Google Scholar] 252. Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull 2012;38:592‐8. [PMC free article] [PubMed] [Google Scholar] 253. Every‐Palmer S, Ellis PM. Clozapine‐induced gastrointestinal hypomotility: a 22‐year bi‐national pharmacovigilance study of serious or fatal ‘slow gut’ reactions, and comparison with international drug safety advice. CNS Drugs 2017;31:699‐709. [PMC free article] [PubMed] [Google Scholar] 254. Hayat U, Dugum M, Garg S. Chronic constipation: update on management. Cleve Clin J Med 2017;84:397‐408. [PubMed] [Google Scholar] 255. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209‐23. [PubMed] [Google Scholar] Page 2Side effect profiles of selected antipsychotic drugs
|
A nurse is caring for a client who is experiencing adverse effects after receiving a new medication
zusammenhängende Posts
Urheberrechte © © 2024 frojeostern Inc.
